GlassScriptPhysician profile
Trisha A Duncan
NPI 1821409988
$4,627.57
in general payments reported to CMS, 2019-2025
31 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $727 · 2021: $595 · 2022: $890 · 2023: $854 · 2024: $277 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.43 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.26 | 2019-2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $520.00 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $481.21 | 2019-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $434.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $337.81 | 2022-2024 | Freestyle Libre 3, Proclaim, Jot Dx |
| Novo Nordisk INC | $269.44 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $242.28 | 2020-2024 | Ubrelvy |
| Astellas Pharma US INC | $199.42 | 2021-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $195.95 | 2022 | |
| Amarin Pharma, INC. | $193.06 | 2019-2021 | |
| Pfizer INC. | $179.25 | 2019-2023 | |
| Glaxosmithkline, LLC. | $139.46 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $111.65 | 2019-2025 | Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $99.81 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.98 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $65.31 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.95 | 2019-2021 | |
| Exact Sciences Corporation | $60.22 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.27 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $44.18 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $36.17 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.37 | 2020 | |
| Sanofi Pasteur INC. | $29.63 | 2020-2023 | |
| Eisai INC. | $27.39 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.20 | 2021 | |
| Vistapharm, INC. | $26.20 | 2021 | |
| Teleflex LLC | $22.71 | 2025 | Barrigel |
| Dynavax Technologies Corporation | $19.52 | 2022 | |
| Hologic Sales and Service, LLC | $18.30 | 2023 | Thinprep 2000 Processor, Aptima |
| Genentech USA, INC. | $14.31 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.